Zodasiran
Based on 1 Customer Validation
Zodasiran is a siRNA targeted to ANGPTL3 in the liver.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.26%
- CAS. Nr.: 2232918-66-8
- Formel: C491H646F13N162O309P43S7
- Molecular Weight:15564.70
-
Speicherung:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Biologische Aktivität
Beschreibung
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 2232918-66-8
-
Appearance Solid
-
Molecular Weight 15564.70
-
Formel C491H646F13N162O309P43S7
-
Color White to off-white
-
SMILES
[Zodasiran]
-
Synonyms
ARO-ANG3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Reinheit & Dokumentation
-
Data Sheet (264 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
Verweise
[1]. Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi Therapeutic targeted to ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):913-925. [Content Brief]
[2]. Kamrul-Hasan ABM, Dutta D, Nagendra L, Mondal S, Bhattacharya S, Kalra S. Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis. Endocr Pract. 2024;30(11):1103-1112. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)